Regenerative Medical Technology (RMTG) Liabilities from Discontinued Operations (2022)
Regenerative Medical Technology (RMTG) posted quarterly Liabilities from Discontinued Operations of 68313.0 for Q4 2022.
Regenerative Medical Technology (RMTG) Liabilities from Discontinued Operations (2022) Analysis & Trends
Regenerative Medical Technology's Liabilities from Discontinued Operations history runs 1 years deep, the most recent figure standing at 68313.0 for Q4 2022.
- In Q4 2022, Liabilities from Discontinued Operations changed N/A year-over-year to 68313.0; the TTM figure through Dec 2022 stood at 68313.0 (changed N/A YoY), while the FY2022 annual figure was 68313.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q4 2022 stood at 68313.0.
- The five-year high for Liabilities from Discontinued Operations was 68313.0 in Q4 2022, with the low at 68313.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 68,313.00 |
| Dec 31, 2022 | 68,313.00 |